StreetAlpha.app
Home › Stocks › HBIO

Harvard Bioscience Inc (HBIO)

$9.08
▲ +1.91%
LAST CLOSE · NOV 17

Harvard Bioscience makes laboratory instruments and software used in life science research and preclinical drug testing. It last closed at $9.08 on Nov 17, up 1.91% on the day.

AI Auto Pilots
Is HBIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$89.4M
+2.3% vs a year ago
Net income
−$11.8M
−13.2% margin
Free cash flow
−$3.2M
−3.5% margin
Gross margin
57.4%
$51.4M gross profit
Valuation
Market cap
$41.5M
4.6M shares
P/E
–
Price to sales
0.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$4.9M
At Sep 30
Debt
$37.2M
At Sep 30
Shareholder equity
$5.1M
Shares outstanding
4.6M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $118.9M$118.9MFY2021FY2022: $113.3M$113.3MFY2022FY2023: $112.3M$112.3MFY2023FY2024: $94.1M$94.1MFY2024FY2025: $86.5M$86.5MFY2025

From HBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated HBIO in the past 90 days.
Average 12-month target
No price targets on HBIO in the past 90 days.
Latest rating changes
BenchmarkMaintained
Aug 12Buy$7.50
DateFirmActionRatingPrice target
Aug 12BenchmarkMaintainedBuy$7.50
Loading…

Technical Analysis

HBIO · as of the Nov 17 close · updated after every close
Uptrend

The stock is 4% above its 20 day and 8% above its 50 day average. It is 27% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 56). The nearest support is the Pivot S1 at $8.82, and the nearest resistance the swing high (Nov 2) at $9.10.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 5.6%/day
Key levels
$10.2052 week high+12.3%
$9.34Pivot R1+2.9%
$9.10Swing high (Nov 2)+0.2%
$9.08Pivot+0.0%
$9.08Last close
$8.82Pivot S1−2.9%
$8.7620 day average−3.5%
$8.3850 day average−7.7%
$8.11Swing low (Nov 6)−10.7%
$7.52100 day average−17.2%
$6.63200 day average−27.0%
$4.0052 week low−55.9%
Indicators
RSI (14)56.10Middle of its rangeNeutral
MACD0.26Above its signal lineBullish
Stochastic50.0Middle of its rangeNeutral
ADX (14)21.0Weak trend
Williams %R-53.6Oversold below −80, overbought above −20Neutral
CCI (20)56.3Oversold below −100, overbought above 100Neutral
Rate of change+4.7%Change over 10 sessionsBullish
ATR (14)$0.51Typical daily range, 5.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for HBIO

What happened before

See how HBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow HBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How HBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in HBIO in the last 90 days.

Loading…

See today’s whale options flow across the market →

HBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼8 buying vs 17 selling
  • ▲Held by funds +2.0 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3237−13.5%
In funds' top 1010–
Held by funds38.7%36.7%+2.0 pts
New / increased2 / 64 / 5−11.1%
Reduced / sold out11 / 615 / 20.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See HBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether HBIO is in one of them and how their past HBIO trades turned out.

HBIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered HBIO in an article yet. Here's the latest on the wider market.

About Harvard Bioscience

Harvard Bioscience makes laboratory instruments, consumables, software and services used in life science research, drug discovery and preclinical testing. Its products include electroporation systems, syringe pumps, spectrophotometers, electrophysiology equipment and telemetry systems that collect data from research animals. Customers include pharmaceutical and biotechnology companies, contract research organizations, universities and government laboratories. The company is based in Holliston, Massachusetts, and sells in the United States, Europe and China.

Headquarters
Holliston, MA
Founded
1901